News >

Encouraging Activity Seen With Glembatumumab Vedotin in Advanced Melanoma

Lynne Lederman, PhD
Published: Friday, Jul 14, 2017

Patrick Ott, MD, PhD

Patrick Ott, MD, PhD

The antibody-drug conjugate (ADC) glembatumumab vedotin (GV) demonstrated an 11% overall response rate (ORR) in patients with refractory advanced melanoma who had received prior treatment with a checkpoint inhibitor and duration of response (DOR) in a phase II study presented at the 2017 ASCO Annual Meeting.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x